Will $3.8 bn-worth HUL-GSK deal profit India unit? What analysts are saying

Shares in Hindustan Unilever rose 4.1 per cent on Monday to a record, while GlaxoSmithKline Consumer Healthcare Ltd. added 2.8 per cent to its highest level since Sept. 21

GlaxoSmithKline, gsk
GSK’s assets include the popular malt-based drinks Horlicks and Boost
Abhishek Vishnoi | Bloomberg
Last Updated : Dec 04 2018 | 12:27 PM IST
A plan by Hindustan Unilever Ltd.’s parent to buy GlaxoSmithKline Plc’s Indian consumer business for 3.3 billion euros ($3.8 billion) in cash and shares is positive for the local unit’s earnings, according to analysts, even as the price tag is said to be about $1 billion more than rival Nestle SA’s offer.

Shares in Hindustan Unilever rose 4.1 percent on Monday to a record, while GlaxoSmithKline Consumer Healthcare Ltd. added 2.8 percent to its highest level since Sept. 21. In London, GlaxoSmithKline slumped 7.6 percent, the most in a decade, while Unilever NV was little changed in Amsterdam.

The buyout “is accretive from both an EPS and margin perspective” and “may lead to ~800-1000 basis points synergy on margins in a phased manner once the merger happens in 12 months time,” Jefferies analysts Varun Lohchab and Tanmay Sharma wrote in a report Monday.

Here’s What Analysts Are Saying:

Credit Suisse (Arnab Mitra)

— Merger will make HUL’s food and refreshment business 1.6x larger and give it a strong nutrition brand which can be leveraged in more categories

— Raises FY21 earnings estimates by 6.5 percent

— Maintains neutral, lifts PT to 1,900 rupees from 1,770 rupees

Citigroup (Jamshed Dadabhoy)

— Deal may take a year to complete given regulatory/shareholder approvals but it should be EPS accretive from day 1

— Even without synergy benefits, the merger is EPS accretive for HUL to the extent of ~3.7% on FY21 earnings estimates 

— HUL may have to pay parent a royalty from Horlicks brand sales

Jefferies (Varun Lohchab)

— HUL’s distribution footprint is ~3x GSK’s, so it has potential to improve sales growth

— Valuations of Hindustan Unilever leave no room for error

— Maintains Hold

Prabhudas Lilladher (Amnish Aggarwal)

— Synergy benefits will start accruing from FY21

— Expects one-time dividend in FY21, given that Glaxo has cash of 38 billion rupees ($539 million) on its books and Hindustan Unilever has 80 percent dividend payout

— Maintains hold, PT 1,880 rupees

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story